Publication date: November 2026 Source: Annals of the Rheumatic Diseases, Volume 85, Issue 11 Author(s): Elise Siegert, Elpida Phithak, Fredrik N. Albach, Robert Biesen, Norman Michael Drzeniek, Maria Dzamukova, Isabell Haase, Klaus Søndergaard, Dorothea Schleser, Leonard Fiebig, Arne Sattler, Ioanna Minopoulou, Marie Chiara Rehm, Phillip Kremer, Udo Schneider, Sofia Trezzini, Anna Maria Claire Rein, Clara Marisa Mayer, Felix Doellinger, Christian Furth
Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis—a case series. // Annals of the Rheumatic Diseases. – URL: https://www.sciencedirect.com/science/article/pii/S0003496726003018?dgcid=rss_sd_all
Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis—a case series. Annals of the Rheumatic Diseases. https://www.sciencedirect.com/science/article/pii/S0003496726003018?dgcid=rss_sd_all
“Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis—a case series.” Annals of the Rheumatic Diseases.
@article{article36015,
title = {Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis—a case series},
journal = {Annals of the Rheumatic Diseases},
url = {https://www.sciencedirect.com/science/article/pii/S0003496726003018?dgcid=rss_sd_all}
}
Objective Black patients with systemic sclerosis (scleroderma) have more severe disease than White patients. We investigated whether racial differences in therapeutic responses to mycophenolate mofetil (MMF) could explain this...